NKGN · As filed with the SEC
NKGen Biotech balance sheet, by quarter
The statement as NKGen Biotech presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD thousands
| USD thousands | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 | Q2 2024 Jun 30, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 6 | 106 | 8 | 79 |
| Restricted cash | 23 | 129 | 229 | 250 |
| Prepaid expenses and other current assets | 2,352 | 2,224 | 674 | 920 |
| Total current assets | 2,381 | 2,459 | 911 | 1,249 |
| Property and equipment, net | 13,024 | 13,297 | 13,576 | 13,856 |
| Operating lease right-of-use asset, net | 341 | 379 | 415 | 450 |
| Capitalized software, net | 96 | 96 | 93 | 93 |
| Total assets | 15,842 | 16,231 | 14,995 | 15,648 |
| Liabilities and Stockholders’ Deficit | ||||
| Current liabilities: | ||||
| Accounts payable and accrued expenses | 16,738 | 15,668 | 16,608 | 15,104 |
| Forward purchase derivative liabilities | 175 | 148 | — | — |
| Forward purchase derivative liabilities | — | — | 118 | 10,511 |
| Tranche Rights | — | — | 70 | 4,336 |
| Convertible Promissory Notes | — | — | 9,709 | 7,259 |
| Convertible Promissory Notes | 18,303 | 32,410 | — | — |
| Convertible Bridge Loans | 196 | 244 | — | 25 |
| Related party loans | 4,000 | 4,000 | 5,000 | 5,000 |
| Revolving line of credit | 4,257 | 5,257 | 4,991 | 4,991 |
| Obligation to issue common stock | — | — | — | 3,617 |
| Operating lease liability, current | 154 | 154 | 154 | 154 |
| Other current liabilities | 65 | 90 | 468 | 411 |
| Total current liabilities | 43,888 | 57,971 | 37,118 | 51,408 |
| Derivative warrant liabilities | 10,995 | 17,073 | 14,008 | 23,236 |
| Senior convertible promissory notes, due to related parties | 11,077 | 10,841 | 10,604 | 10,372 |
| Operating lease liability, non-current | 206 | 246 | 282 | 316 |
| Deferred tax liabilities | 8 | 8 | 33 | 33 |
| Total liabilities | 66,174 | 86,139 | 62,045 | 85,365 |
| Stockholders’ deficit: | ||||
| Common stock, $0.0001 par value; 500,000,000 authorized shares as of March 31, 2025 and December 31, 2024; 51,306,712 and 44,238,754 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 5 | 4 | 4 | 3 |
| Additional paid-in capital | 140,911 | 136,686 | 130,199 | 124,586 |
| Subscription receivable | (182) | (182) | (251) | (10,706) |
| Receivable from shareholder | — | 0 | 0 | 0 |
| Accumulated deficit | (191,066) | (206,416) | (177,002) | (183,600) |
| Total stockholders’ deficit | (50,332) | (69,908) | (47,050) | (69,717) |
| Total liabilities and stockholders’ deficit | 15,842 | 16,231 | 14,995 | 15,648 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.